Wang et al. evaluated the prognostic value of the HER2 status on CTC in advanced-stage breast cancer patients with HER2-negative tumors and found that, among the patients with high-risk HER2-positive CTC, those who received anti-HER2 targeted therapies had an improved PFS compared with those who did not [20]. Here, ERBB2 is linked to breast carcinoma.